Browsing Tag
Gilead Sciences
52 posts
Cognizant expands AI-driven partnership with Gilead to advance digital transformation in biopharma
Cognizant has reinforced its strategic collaboration with Gilead Sciences in a renewed effort to drive AI-driven solutions and…
Gilead Sciences’ seladelpar gains support as PBC treatment in Europe
In a significant milestone for liver disease therapeutics, Gilead Sciences, Inc. has announced that the Committee for Medicinal…
Dr. Reddy’s joins forces with Gilead Sciences to launch HIV drug Lenacapavir in India and 120 countries
In a historic development for HIV treatment worldwide, Dr. Reddy’s Laboratories has announced a new partnership with Gilead…
Unbelievable cure: German man beats HIV after revolutionary treatment
In a groundbreaking development in the fight against HIV, a 60-year-old German man has been declared free of…
Gilead and Arcus announce significant advancement in metastatic colorectal cancer treatment with etrumadenant plus zimberelimab regimen
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) have released promising new data from their…
Gilead Sciences completes $4.3bn acquisition of CymaBay Therapeutics to enhance liver disease portfolio
Gilead Sciences, Inc. (Nasdaq: GILD) has officially announced the successful acquisition of CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for…
Gilead Sciences to acquire CymaBay Therapeutics to enhance liver disease portfolio
In a significant move within the biopharmaceutical industry, Gilead Sciences, Inc. (Nasdaq: GILD) has confirmed its acquisition of…
Gilead Sciences invests $320m in Arcus Biosciences to accelerate cancer treatment innovations
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) have announced a significant amendment to their…
Strides Pharma subsidiary gains FDA approval for EET tablets
Strides Pharma Science Limited has announced a significant achievement, with its wholly-owned subsidiary, Strides Pharma Global Pte. Limited…
Gilead’s EVOKE-02 study of Trodelvy, KEYTRUDA combo shows promise in NSCLC
Gilead Sciences, Inc. announced early data showcasing promising clinical activity of Trodelvy in combination with Merck’s KEYTRUDA for…